Sehitkamil

Childbirth is a significant experience in women's lives that can greatly affect their quality of life. Pain and fear during labor are linked to negative outcomes such as lower childbirth satisfaction, preference for cesarean section, longer and more difficult labor, and postpartum depression. This research aims to evaluate the effects of Pilates ball exercises and manual sacral massage on labor pain, labor duration, and childbirth satisfaction through a randomized controlled study. The study will take place between December 1, 2024 and May 1, 2025 in two public hospitals affiliated with the Gaziantep Provincial Health Directorate. A total of 105 pregnant women will be divided into three groups: 35 will perform Pilates ball exercises, 35 will receive sacral massage, and 35 will be in a control group. These interventions will be applied during the active phase of labor. The Pilates ball group will perform pelvic oscillation movements once every hour, while the sacral massage group will receive stroking and vibration techniques to the sacral area during contractions, also once an hour for up to 10 minutes. Participants will be assessed using several forms including Personal Information Form, Labor Monitoring Form, and Application Monitoring Form to record the number and duration of interventions. Labor pain will be measured using a Visual Analog Scale, labor duration with a Partograph, and maternal satisfaction with a Labor Satisfaction Scale. Data will be analyzed to determine how Pilates ball exercises and sacral massage affect labor pain intensity, labor length, and childbirth satisfaction.

Researchers are evaluating the effectiveness of brenetafusp (IMC-F106C) combined with nivolumab compared to standard nivolumab treatments in people who have advanced melanoma that has not been treated before. This study focuses on participants who have a specific genetic marker called HLA-A*02:01 and aims to understand how these treatments affect the progression of their cancer. The study is a phase 3, randomized, controlled trial, which helps ensure reliable comparison between the different treatment regimens. Participants in this study will receive either brenetafusp plus nivolumab or standard nivolumab regimens, which may include nivolumab alone or in combination with relatlimab. These treatments are given by intravenous infusion, with specific dosing of the drugs as concentrates for infusion. The study compares these approaches to see which is more effective in controlling the melanoma. During the study, participants will be closely monitored for disease progression and overall health. Researchers will use scans and other assessments to measure progression-free survival, which is the time participants live without their disease worsening, followed for up to about 45 months. Safety and response to treatment will be regularly evaluated to better understand the effects of the therapies over time.